TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma.
Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Alderley Park, Congleton Road,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- evgen.com
- Keywords
- Pharmaceuticals, Cancer and neurological conditions, Core technology Sulforadex®, Commercialising sulforaphane-based pharmaceuticals.
- HQ
- Nether Alderley, Cheshire
Theracryf Questions
Theracryf's website is evgen.com
Theracryf's LinkedIn profile is https://uk.linkedin.com/company/theracryf
Theracryf has
8 employees.
View email and phone details for 8
employees at Theracryf.
Theracryf's industry is
Biotechnology Research
Theracryf's top competitors are
Iduron,
Spirea,
Roquefort Therapeutics Plc,
Orbit Discovery,
Infex Therapeutics,
Dark Blue Therapeutics,
Chronos Therapeutics,
Nodus Oncology,
Obn (Uk) Ltd,
Duke Street Bio.
Theracryf's categories are Biotechnology Research
Theracryf's founding year is 2007
